phrykt

TransMedics Group, Inc. (TMDX): who owns it and who trades it

As of Nov 16, 2026, TMDX insiders reported 13 open-market sales worth $4.7M and 2 purchases worth $1.1M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gerardo Hernandez (CFO), with $1.2M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling TransMedics Group

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TMDX

374 funds and institutions reported TMDX shares worth $2.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.16.2%
FMR LLC (Fidelity)14.9%
Vanguard Portfolio Management LLC5.6%
Vanguard Capital Management LLC4.3%
State Street Corp4.1%
Nomura Asset Management International Inc.2.6%
Geode Capital Management, LLC2.6%
Hood River Capital Management LLC2.2%
Dimensional Fund Advisors LP1.8%
Braidwell LP1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.60M16.19%$372M+6%
FMR LLC (Fidelity)5.13M14.85%$341M+1%
Vanguard Portfolio Management LLC1.93M5.60%$128M+1%
Vanguard Capital Management LLC1.50M4.33%$99.5M+1%
State Street Corp1.42M4.11%$94.3M+8%
Nomura Asset Management International Inc.910,4952.63%$60.5M+3%
Geode Capital Management, LLC894,9132.59%$59.5M+7%
Hood River Capital Management LLC751,1332.17%$49.9M+7%
Dimensional Fund Advisors LP610,1071.77%$40.5M+18%
Braidwell LP609,7151.76%$40.5M+85%
Goldman Sachs Group Inc559,7711.62%$37.2M-35%
Citadel Advisors LLC558,8241.62%$37.1M+807%
Eventide Asset Management, LLC548,8741.59%$36.5MNo change
Wellington Management Group LLP515,9731.49%$34.3M+6%
Emerald Advisers, LLC490,4911.42%$32.6M+43%
UBS Group AG488,0581.41%$32.4M-16%
Morgan Stanley405,1121.17%$26.9M-42%
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC398,2501.15%$26.5M-58%
Invesco Ltd.394,9791.14%$26.2M-62%
Citigroup Inc386,0661.12%$25.6M+8%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TMDX insiders reported $1.1M of open-market purchases and $4.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.1M
2 trades, 2 people
Sales, 12 months
$4.7M
13 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 9, 2026
Filed Nov 12, 2026

Purchases and sales by month

$2.4M$2.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 9, 2026James R TobinDirectorSale59$93.96$5.5KForm 4
Nov 9, 2026James R TobinDirectorSale4,000$94.98$380KForm 4
Sep 11, 2026David WeillDirectorPurchase1,336$81.63$109KForm 4
Jun 15, 2026Thomas J. GundersonDirectorSale9,624$75.06$722KForm 4
Mar 4, 2026Stephanie LovellDirectorSale1,193$149.62$178KForm 4
Mar 4, 2026David WeillDirectorSale3,571$146.82$524KForm 4
Mar 4, 2026Gerardo HernandezCFOSale1,324$147.21$195KForm 4
Mar 4, 2026Gerardo HernandezCFOSale5,912$147.21$870KForm 4
Mar 2, 2026Gerardo HernandezCFOSale375$139.12$52.2KForm 4
Mar 2, 2026Anil P. RanganathSee remarksSale864$139.12$120KForm 4
Mar 2, 2026Nicholas CorcoranSee remarksSale2,966$139.12$413KForm 4
Dec 4, 2025Gerardo HernandezCFOSale920$139.62$128KForm 4
Dec 3, 2025David WeillDirectorSale5,000$138.64$693KForm 4
Nov 25, 2025Anil P. RanganathSee remarksSale3,000$145.22$436KForm 4
Nov 17, 2025Waleed H HassaneinCEOPurchase8,775$114.00$1MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
David WeillDirector$109K$1.2MSep 11, 2026
Gerardo HernandezChief Financial Officer–$1.2MMar 4, 2026
Waleed H HassaneinPresident & CEO, Director$1M–Nov 17, 2025
Thomas J. GundersonDirector–$722KJun 15, 2026
Anil P. RanganathSee remarks–$556KMar 2, 2026
Nicholas CorcoranSee remarks–$413KMar 2, 2026
James R TobinDirector–$385KNov 9, 2026
Stephanie LovellDirector–$178KMar 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TMDX short interest

Very high short interest. 25.6% of TMDX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.88M TMDX shares were sold short, 25.6% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 869,058 shares, buying them all back would take about 10.2 trading days (days to cover).

Shares short, % of all shares

25.6%May 15Oct 3026.2%

Days to cover

10.2May 15Oct 3014.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.88M25.60%+1%869,05810.2
Oct 15, 20268.77M25.29%+3%886,8639.9
Sep 30, 20268.55M24.66%+7%654,56213.1
Sep 15, 20267.98M23.01%-1%747,12410.7
Aug 31, 20268.08M23.30%+2%632,34712.8
Aug 14, 20267.91M22.81%+3%1.18M6.7
Jul 31, 20267.67M22.13%-1%807,8669.5
Jul 15, 20267.72M22.32%-2%809,0779.5
Jun 30, 20267.87M22.76%+2%1.30M6.0
Jun 15, 20267.68M22.22%+4%1.07M7.2
May 29, 20267.36M21.29%-10%1.38M5.3
May 15, 20268.18M23.66%-2%2.42M3.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

TransMedics Group company events

TransMedics Group filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 10, 2026LeadershipThe Board of Directors of TransMedics Group, Inc. appointed Fernando Araujo as Chief Financial Officer and Treasurer, effective as of September 21, 2026. Filing
  3. Aug 4, 2026ResultsReleased financial results. Filing
  4. May 21, 2026VoteReported shareholder vote results. Filing
  5. May 5, 2026ResultsReleased financial results. Filing
  6. Feb 27, 2026ResultsReleased financial results. Filing
  7. Feb 24, 2026ResultsReleased financial results. Filing
  8. Feb 4, 2026LeadershipThe Board of Directors of TransMedics Group, Inc. appointed Giovanni Cecere as Chief Commercial Officer, effective as of February 2, 2026. Filing
  9. Jan 12, 2026AgreementTransMedics Group, Inc. entered into a lease agreement with BioMed Realty for the lease of approximately 498,286 square feet of space located at 188 Assembly Park Drive, Somerville, MA 02145 for the Company’s principal executive offices and for research and development, laboratory, manufacturing… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

TransMedics Group financials

Famous investors that hold TMDX

3 of the 50 well-known investors we track reported holding TMDX in their latest 13F filing. The largest position is Ken Griffin's, worth $53.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026645,653$53.9M0.0%+16%
Israel Englander · Millennium ManagementQ3 2026148,939$12.4M0.0%-40%
Paul Tudor Jones · Tudor Investment CorpQ3 202613,207$1.1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about TransMedics Group, Inc. (TMDX) stock

Who owns the most TMDX stock?

The largest reported owner of TransMedics Group, Inc. (TMDX) is BlackRock, Inc., with 16.2% of the company. In total, 374 funds and institutions reported holding TMDX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are TMDX insiders buying or selling?

In the last 12 months, TMDX insiders reported 2 open-market purchases worth $1.1M and 13 sales worth $4.7M. The latest trade was on Nov 9, 2026. See every trade.

What is the short interest in TMDX?

As of Oct 30, 2026, 8.88M TMDX shares were sold short, 25.6% of the shares outstanding, up 1.2% from the report before. At the average daily volume of 869,058 shares, buying them all back would take about 10.2 trading days (days to cover). See the history.

Which famous investors hold TMDX?

3 of the 50 well-known investors we track reported TMDX in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $53.9M. See all holders.

Executive pay

TransMedics Group's chief executive was paid a total of $10.9M for the year ended Dec 31, 2025, up 33% from $8.2M the year before. In the last 12 months, TransMedics Group's executives and directors bought $1.1M of stock on the open market and sold $4.7M.

Chief executive, total pay$10.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$26.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.